作者
Gilles Montalescot, Harvey D White, Richard Gallo, Marc Cohen, P Gabriel Steg, Philip EG Aylward, Christoph Bode, Massimo Chiariello, Spencer B King III, Robert A Harrington, Walter J Desmet, Carlos Macaya, Steven R Steinhubl
发表日期
2006/9/7
期刊
New England Journal of Medicine
卷号
355
期号
10
页码范围
1006-1017
出版商
Massachusetts Medical Society
简介
Background
Despite its limitations, unfractionated heparin has been the standard anticoagulant used during percutaneous coronary intervention (PCI). Several small studies have suggested that intravenous enoxaparin may be a safe and effective alternative. Our primary aim was to assess the safety of enoxaparin as compared with that of unfractionated heparin in elective PCI.
Methods
In this prospective, open-label, multicenter, randomized trial, we randomly assigned 3528 patients with PCI to receive enoxaparin (0.5 or 0.75 mg per kilogram of body weight) or unfractionated heparin adjusted for activated clotting time, stratified according to the use or nonuse of glycoprotein IIb/IIIa inhibitors. The primary end point was the incidence of major or minor bleeding that was not related to coronary-artery bypass grafting. The main secondary end point was the percentage of patients in whom the target anticoagulation …
引用总数
2006200720082009201020112012201320142015201620172018201920202021202220232024545455342522928342221181112710934
学术搜索中的文章
G Montalescot, HD White, R Gallo, M Cohen, PG Steg… - New England Journal of Medicine, 2006
G Montalescot, R Gallo, HD White, M Cohen, PG Steg… - JACC: Cardiovascular Interventions, 2009